ArticleIntensive care medicine experimental2025
The ADVanced Organ Support (ADVOS) hemodialysis system balances blood pH within 24 h in patients with multiple organ failure and hypercapnic acidosis.
Article in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracorporeal Multiorgan Support During Prone Positioning in Severe ARDS: A Physiologic Proof-of-Concept Study.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere hypercapnia, especially when associated with acidosis, should be avoided or actively managed, as it is an independent risk factor in critically ill patients. The ADVOS multi hemodialysis system offers the potential to correct acidosis and hypercapnia through customizable pH and bicarbonate content within the dialysate fluid. The aim of this work is to analyze the exact timing for pH correction and the main factors leading to it in patients with multiple organ failure (MOF) and hypercapnic acidosis treated with ADVOS.
methodsPatients with MOF and metabolic or hypercapnic acidosis (pH < 7.35) were included over a study period of 13 months. All patients received at least one treatment with ADVOS hemodialysis system for at least 24 h. The primary outcome was the time to blood pH ≥ 7.35.
results24 patients with a median age of 61 years and a median SOFA score of 15 points were included. The results of 134 ADVOS sessions, with a median of 5 sessions per patient, were analyzed. Median time to blood pH ≥ 7.35 was 4 h; a significant blood pH increase within 24 h was reached in all patients (7.21 before vs. 7.39 after, p < 0.01).
conclusionsA single session of ADVOS corrected blood pH and supported the reduction of pCO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.